We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
American Express (AXP) Q2 Earnings & Revenues Beat, Up Y/Y
Read MoreHide Full Article
American Express Co. (AXP - Free Report) second-quarter 2019 earnings of $2.07 per share surpassed the Zacks Consensus Estimate by 0.98% and were up 12.5% year over year.
Total revenues of $10.8 billion beat the Zacks Consensus Estimate by 0.14% and were up 8.4% year over year. This is the eighth straight quarter in which the company posted foreign exchange adjusted revenue growth of more than 8%. This growth continues to be driven by a well balanced mix of spending, fees and loans spread across geographies and customer segments.
The company continues to witness solid trends in Card Member spending led by consumers. This spending can be attributed to an economy that is growing but at a modest pace relative to 2018.
American Express Company Price, Consensus and EPS Surprise
Provisions for loss totaled $861 million, up 7% year over year, which was attributable to growth in loan (up 11% year over year), receivable portfolio and an increase in higher write-offs.
Total expenses of $7.8 billion increased 9% year over year, due to growth in rewards and other customer engagement costs driven by increased Card Member spending, higher usage of card benefits and continued investments in co-brand partnerships.
During the quarter, the company added 2.9 million new proprietary cards.Nearly 70% of these new cards carry an annual fee, which reinstates the fact that Card Members are taking up cards and willing to pay for premium value.
Segment Update
Strong Segmental Results
American Express’ Global Consumer Services segment reported net income of $738 million, down 4% year over year. Total revenues, net of interest expenses of $5.8 billion, were up 10% year over year, reflecting higher loans and Card Member spending as well as fee income.
Global Commercial Services’ net income of $644 million was up 14% year over year. Total revenues, net of interest expenses, increased 7% year over year to $3.4 billion, primarily reflecting higher Card Member spending.
Global Merchant and Network Services’ net income rose 16% year over year to $632 million in the reported quarter. Total revenues and net of interest expenses were up 5% year over year to $1.7 billion.
Guidance Update
American Express has reaffirmed its financial guidance for 2019. The company expects revenue growth of 8%–10% this year. In addition, its adjusted EPS guidance range for 2019 is $7.85–$8.35.
The company also expects to increase the regular quarterly dividend by 10.3% to 43 cents per share, beginning with the third quarter of 2019, subject to approval by its board of directors.
Here are some finance stocks that you may want to consider as our model shows that these have the right combination of elements to beat on earnings in the upcoming releases.
Discover Financial Services (DFS - Free Report) has an Earnings ESP of +0.18% and a Zacks Rank #3 (Hold).
PayPal Holdings, Inc. (PYPL - Free Report) has an Earnings ESP of +11.19% and a Zacks Rank of 2 (Buy).
Mastercard Inc. (MA - Free Report) has an Earnings ESP of +0.55% and a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
American Express (AXP) Q2 Earnings & Revenues Beat, Up Y/Y
American Express Co. (AXP - Free Report) second-quarter 2019 earnings of $2.07 per share surpassed the Zacks Consensus Estimate by 0.98% and were up 12.5% year over year.
Total revenues of $10.8 billion beat the Zacks Consensus Estimate by 0.14% and were up 8.4% year over year. This is the eighth straight quarter in which the company posted foreign exchange adjusted revenue growth of more than 8%. This growth continues to be driven by a well balanced mix of spending, fees and loans spread across geographies and customer segments.
The company continues to witness solid trends in Card Member spending led by consumers. This spending can be attributed to an economy that is growing but at a modest pace relative to 2018.
American Express Company Price, Consensus and EPS Surprise
American Express Company price-consensus-eps-surprise-chart | American Express Company Quote
Provisions for loss totaled $861 million, up 7% year over year, which was attributable to growth in loan (up 11% year over year), receivable portfolio and an increase in higher write-offs.
Total expenses of $7.8 billion increased 9% year over year, due to growth in rewards and other customer engagement costs driven by increased Card Member spending, higher usage of card benefits and continued investments in co-brand partnerships.
During the quarter, the company added 2.9 million new proprietary cards.Nearly 70% of these new cards carry an annual fee, which reinstates the fact that Card Members are taking up cards and willing to pay for premium value.
Segment Update
Strong Segmental Results
American Express’ Global Consumer Services segment reported net income of $738 million, down 4% year over year. Total revenues, net of interest expenses of $5.8 billion, were up 10% year over year, reflecting higher loans and Card Member spending as well as fee income.
Global Commercial Services’ net income of $644 million was up 14% year over year. Total revenues, net of interest expenses, increased 7% year over year to $3.4 billion, primarily reflecting higher Card Member spending.
Global Merchant and Network Services’ net income rose 16% year over year to $632 million in the reported quarter. Total revenues and net of interest expenses were up 5% year over year to $1.7 billion.
Guidance Update
American Express has reaffirmed its financial guidance for 2019. The company expects revenue growth of 8%–10% this year. In addition, its adjusted EPS guidance range for 2019 is $7.85–$8.35.
The company also expects to increase the regular quarterly dividend by 10.3% to 43 cents per share, beginning with the third quarter of 2019, subject to approval by its board of directors.
American Express carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Here are some finance stocks that you may want to consider as our model shows that these have the right combination of elements to beat on earnings in the upcoming releases.
Discover Financial Services (DFS - Free Report) has an Earnings ESP of +0.18% and a Zacks Rank #3 (Hold).
PayPal Holdings, Inc. (PYPL - Free Report) has an Earnings ESP of +11.19% and a Zacks Rank of 2 (Buy).
Mastercard Inc. (MA - Free Report) has an Earnings ESP of +0.55% and a Zacks Rank of 3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>